|
The Use of Annexins in Preventing and Treating Muscle Membrane Injury
NU 2018-119
INVENTORS
Elizabeth McNally*
Alexis Demonbreun
SHORT DESCRIPTION
An annexin-based biological therapeutic that enhances the body's natural cell membrane repair process to reduce muscle cell death and preserve tissue function.
BACKGROUND
Cell membrane integrity is critical for survival, especially in tissues under constant mechanical...
Published: 12/9/2025
|
Inventor(s):
Keywords(s): Neurodegenerative disease, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Novel 2-Imidazolyl-Pyrimidine Inhibitors for Neurodegenerative Disease Therapeutics
NU 2014-101
INVENTORS
Richard Silverman*
Paramita Mukherjee
SHORT DESCRIPTION
This invention introduces novel 2-imidazolyl-pyrimidine scaffolds that inhibit neuronal nitric oxide synthase. It offers potential for drug development targeting Parkinson’s and other neurodegenerative diseases.
BACKGROUND
Neurodegenerative disorders such as...
Published: 12/3/2025
|
Inventor(s):
Keywords(s): Biomedical, Materials, Neurodegenerative disease, Neurologic disease, Neurology, Small molecule, Therapeutics
Category(s): Physical Sciences > Materials and Industrial Processes
|
|
2-(Pyridin-3-yl)quinazoline compounds as glucocerebrosidase modulators
✅ Feedback form for Tech ID 2015-064
PROPOSED TITLE: 2-(Pyridin-3-yl) quinazoline Compounds as Glucocerebrosidase Modulators
NU 2015-064
INVENTORS
Richard Silverman*
Dimitri Krainc
Jianbin Zheng
SHORT DESCRIPTION
Novel substituted quinazoline compounds that modulate glucocerebrosidase activity, offering a promising therapeutic approach for...
Published: 11/18/2025
|
Inventor(s):
Keywords(s): Neurodegenerative disease, Neurologic disease, PD - Parkinson's Disease, Research tool, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Development of Therapeutics for Amyotrophic Lateral Sclerosis (ALS)
NU 2008-163 and NU2009-098
Inventors
Richard B. Silverman*
Richard Morimoto
P. Hande Ozdinler
Short Description
Three series of New Chemical Entities (NCEs) that exhibit efficacy in an ALS animal model
Background
ALS causes muscle weakness and atrophy due to the degeneration of the upper and lower motor neurons. This disease is both genetic...
Published: 11/18/2025
|
Inventor(s):
Keywords(s): Neurodegenerative disease, Neurologic disease, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Pyrimidine-2,4,6-Trione Derivatives Preparation and Their Use for the Treatment of Amyotrophic Lateral Sclerosis (ALS) ALS Therapy
NU 2009-072
INVENTORS
Richard Morimoto*
Richard Silverman*
Gavin Guoyao Xia
SHORT DESCRIPTION
This invention discloses novel pyrimidine-2,4,6-trione derivatives (PYT compounds) that prevent abnormal protein aggregation associated with ALS, offering a promising new therapeutic approach for neurodegenerative diseases.
BACKGROUND
Amyotrophic...
Published: 11/18/2025
|
Inventor(s):
Keywords(s): ALS - Amyotrophic Lateral Sclerosis, Neurodegenerative disease, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Potent and selective Cav1.3 negative allosteric modulators for use in Parkinson's Disease
NU 2010-105 and NU 2024-179
INVENTORS
Richard Silverman* (Northwestern University, Weinberg College of Arts & Science, Department of Chemistry)
Dalton Surmeier Jr.* (Northwestern University, Feinberg School of Medicine, Chair of the Department of Neuroscience)
Garry Cooper
Soosung Kang
Jack Nguyen
SHORT DESCRIPTION
For pharmaceutical...
Published: 11/11/2025
|
Inventor(s):
Keywords(s): Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease
Category(s): Life Sciences > Therapeutics
|
|
A Novel Combination Therapy for Parkinson’s Disease
NU 2013-149
INVENTORS
Dalton Surmeier Jr. (Northwestern University, Feinberg School of Medicine, Chair of the Department of Neuroscience)*
Daniel Galtieri
Ema Ilijic
Enrico Zampese
Jaime Guzman-Lucero
Javier Sanchez
SHORT DESCRIPTION
This technology uses a low-dose combination of two FDA-approved compounds to reduce oxidative stress in neurons...
Published: 11/6/2025
|
Inventor(s):
Keywords(s): Biomedical, Drug delivery, Neurodegenerative disease, Neurologic disease, PD - Parkinson's Disease, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Cell-type specific disruption of M1 muscarinic acetylcholine receptor expression to alleviate Parkinson's disease
NU 2024-244
INVENTORS
Dalton J. Surmeier Jr*
Tatiana Tkatch
Shenyu Zhai
SHORT DESCRIPTION
Gene therapy targeting M1 muscarinic receptor expression in striatal spiny projection neurons to enhance levodopa response and slow Parkinson’s Disease progression.
BACKGROUND
Parkinson’s Disease (PD) is the second most common age-related...
Published: 1/5/2026
|
Inventor(s):
Keywords(s): CNS - Central Nervous System, Gene therapy, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Gene therapy for levodopa-induced dyskinesia
NU 2024-086
INVENTORS
Dalton J. Surmeier Jr*
Weixing Shen
Shenyu Zhai
Tatiana Tkatch
Qiaoling Cui
Zhong Xie
SHORT DESCRIPTION
Gene therapy targeting GRIN2B in striatal spiny projection neurons to treat levodopa-induced dyskinesia.
BACKGROUND
Parkinson’s Disease (PD) is the second most common age-related neurodegenerative disease...
Published: 1/5/2026
|
Inventor(s):
Keywords(s): CNS - Central Nervous System, Dyskinesis, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Therapeutic Intervention for ALS and Dementia
NU 2021-058
INVENTORS
Evangelos Kiskinis*
Juan Alberto Ortega Cano Marco Boccitto
SHORT DESCRIPTION
Design of an RNA-based oligonucleotide that protects from dipeptide repeat protein toxicity for the treatment of ALS and FTD.
BACKGROUND
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are devastating neurodegenerative diseases...
Published: 12/18/2025
|
Inventor(s):
Keywords(s): ALS - Amyotrophic Lateral Sclerosis, CNS - Central Nervous System, DPR - Dipeptide Repeat Proteins, FTD - Frontotemporal Dementia, Neurodegenerative disease, Neurology, RNA - Ribonucleic Acid, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|